Clinical Trials Logo

Respiration, Artificial clinical trials

View clinical trials related to Respiration, Artificial.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT00871039 Withdrawn - Alcoholism Clinical Trials

Pilot Study Evaluating Stress Response and Immune Function in Mechanically Ventilated Patients With Alcohol Use Disorders Treated With Propofol or Midazolam

Start date: March 2009
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the effects of the sedatives propofol and midazolam on stress response and immune function in critically ill patients with alcohol use disorders who are undergoing mechanical ventilation.

NCT ID: NCT00652756 Withdrawn - Clinical trials for Respiration, Artificial

Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation

iVent
Start date: August 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the use of the VersaMed iVent ventilator in the acute care setting, hypothesizing that, in comparison to the standard approach, the use of the VersaMed will facilitate transport and reduce transport-associated complications while providing equivalent ventilatory support and transport success rates for both intubated patients and patients receiving noninvasive ventilation.

NCT ID: NCT00536445 Withdrawn - Infant, Premature Clinical Trials

Use of NAVA in Intubated Preterm

Start date: October 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The present protocol will demonstrate the feasibility and efficacy of a newly developed mode of mechanical ventilation, Neurally Adjusted Ventilatory Assist, commonly known as NAVA. During NAVA, the timing and magnitude of pressure delivered are controlled by the infants' diaphragm electrical activity (EAdi), a validated measurement of neural respiratory drive. Recent clinical trials in adults and term infants have shown that NAVA is more synchronous than conventional pressure support ventilation, and that NAVA delivers lower mean airway pressures to achieve the same ventilation and respiratory muscle unloading. NAVA has recently been approved for use in neonates by Health Canada and the FDA in the United States, and is commercially available on the Servoi ventilator (Maquet Critical Care, Solna, Sweden). The present protocol is designed as a "case study" where the researchers responsible would like to evaluate the feasibility and efficacy of ventilating a premature baby on NAVA with the Servoi for 12 hours.